SCOTTSDALE, AZ / ACCESSWIRE / June 9, 2015 / THC Farmaceuticals, Inc. (OTCQB: CBDG): today announced that Ed Rosenthal, a noted horticulturist, author and publisher is joining CBDG as President of the Company, officially taking up his duties June 15th, 2015. Mr. Rosenthal has also agreed to serve as a director of CBDG upon appointment.
Rosenthal is a noted researcher and writer who has specialized in marijuana studies for more than 35 years. One of his discoveries was identifying terpenes as important components of marijuana, which he chronicled in his work "Big Book of Buds Vol. 3." Properties of the marijuana plant includes the psychoactive THC, the medically promising cannabinoids (CBD's) and Terpenes, whose cumulative effect was later identified by Dr. Raphael Mechoulum, Dean of marijuana researchers, as "The Entourage Effect."
Rosenthal plans to lead a team of researchers in developing targeted intermediary phytochemical combinations that can be used in production of both cannabinoid and non-cannabinoid based products.
Rosenthal estimates that the first products based on this research will complete trial within six months and will be on store shelves within a year. He stated, "I appreciate the opportunity to lead this research program to develop new and better plant based medicines."
This inclusion of Ed Rosenthal to THC Farmaceuticals brings to the company the knowledge base of one of the cannabis industries' foremost horticulturist and activists. As an industry leader and cannabis expert, Mr. Rosenthal will help guide the company's expansion into cannabis and cannabis related business.
Chief Executive Officer and Former US Senator Mike Gravel stated, "Ed is incredibly knowledgeable; his experience in and connection with the cannabis industry is unparalleled. We already had lofty expectations at THC Farmaceuticals and we're happy to have secured Rosenthal's services and are looking forward to working closely with the research team he is assembling. This team will create a new genre of cannabinoid medicinals that will offer patients more choice of effective treatments. With the addition of Ed Rosenthal, we now have 'high' expectations."
About THC Farmaceuticals, Inc.:
CBDG owns and operates ATMs placed in high-traffic commercial areas in Utah and CBDG is now expanding its operations to include businesses and intellectual properties related to the hemp and cannabis industries.
For additional information, contact Eric Miller at (480) 725-9060.
Forward-Looking Statements:
This press release contains "forward-looking statements." Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
SOURCE: THC Farmaceuticals, Inc.
